The Johnson & Johnson COVID-19 vaccine is no longer available because its manufacturer, Janssen Biotech, voluntarily asked the FDA to withdraw its emergency use authorization in May 2023. The FDA formally revoked the authorization on June 1, 2023. The decision reflected a combination of factors: a rare but serious blood-clotting side effect, manufacturing problems, declining demand, and the CDC’s official preference for mRNA vaccines over the J&J shot.
The Manufacturer Pulled It From the Market
On May 22, 2023, Janssen Biotech told the FDA that the last government-purchased lots of the vaccine had expired, that there was no demand for new lots in the United States, and that the company had no plans to update the vaccine’s formula to target newer variants. The FDA revoked the emergency use authorization ten days later. This was not a sudden safety recall. It was the formal end of a vaccine that had already been sidelined for over a year.
A Rare Clotting Disorder Raised Early Alarms
The most significant safety concern was a condition called thrombosis with thrombocytopenia syndrome, or TTS. People who developed TTS formed dangerous blood clots while simultaneously having abnormally low levels of the platelets that help blood clot, a paradox that made the condition especially hard to treat. Cases occurred at a rate of roughly 1.7 to 3.7 per million doses of the J&J vaccine, and the condition carried a mortality rate around 32% in reported cases from low- and middle-income countries.
The U.S. paused distribution of the vaccine in April 2021 after six cases of TTS were identified among nearly seven million doses given. The pause lasted about ten days while regulators investigated. Distribution resumed with a warning label, but the damage to public confidence was significant. The risk was small in absolute terms, yet the availability of two mRNA alternatives with no TTS signal made it hard to justify continued use.
The CDC Officially Preferred mRNA Vaccines
In December 2021, the CDC’s Advisory Committee on Immunization Practices took the unusual step of formally recommending Pfizer and Moderna’s mRNA vaccines over the J&J shot for all adults 18 and older. CDC Director Rochelle Walensky endorsed the recommendation, stating it reflected the agency’s commitment to providing real-time scientific guidance. This was not a ban, but it effectively made the J&J vaccine a last resort, reserved mainly for people who couldn’t or wouldn’t take an mRNA vaccine. Demand dropped sharply after that announcement.
Manufacturing Problems Undercut Trust
Before the CDC’s preference shift, serious quality-control failures at the Emergent BioSolutions plant in Baltimore had already shaken confidence in the vaccine’s production. An FDA inspection in April 2021 found that a batch of J&J vaccine drug substance had been contaminated with material from a different virus being manufactured in the same facility. The problems went far beyond a single contaminated batch.
Inspectors documented peeling paint on walls and floors in manufacturing areas, loose debris and a stray washer on the floor of a room actively being used for vaccine production, brown and black residue on walls, and overcrowded warehouse spaces. Workers were observed throwing unsealed bags of special medical waste into a service elevator, violating the facility’s own safety procedures. The waste decontamination equipment was inadequate for the volume of material being processed.
These findings led to millions of doses being held up or discarded and forced a lengthy remediation process. The contamination and facility issues compounded the public perception that the J&J vaccine was the lesser option among the three authorized in the U.S.
What This Means If You Got the J&J Vaccine
If your only COVID-19 vaccination was the single-dose J&J shot, you are considered previously vaccinated but should get an updated vaccine. Current CDC guidance for the 2025–2026 season recommends one dose of an updated COVID-19 vaccine (from Moderna, Novavax, or Pfizer) for anyone ages 12 to 64 who was previously vaccinated with any COVID-19 product, including J&J. The recommended wait is at least eight weeks after your last dose for most options.
If you’re 65 or older, the CDC recommends two doses of the updated vaccine, spaced about six months apart. Your original J&J dose still counts as part of your vaccination history. You don’t need to start over or take any extra steps beyond what’s recommended for everyone updating their protection.
Why It Disappeared Gradually, Not Overnight
The J&J vaccine didn’t vanish in a single dramatic moment. It was a slow fade driven by compounding problems. The TTS clotting risk emerged in spring 2021. The manufacturing failures surfaced around the same time. The CDC’s formal preference for mRNA vaccines came in late 2021. By early 2023, remaining U.S. stock was expiring, nobody was requesting new supply, and Janssen had no interest in reformulating the vaccine for newer variants. The formal revocation in June 2023 simply made official what had been true in practice for months: the J&J COVID-19 vaccine was done.